These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15596555)

  • 1. Letter regarding article by Ridker et al, "Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?".
    Lloyd-Jones DM; Greenland P
    Circulation; 2004 Dec; 110(24):e532. PubMed ID: 15596555
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical significance of high-sensitivity C-reactive protein].
    Ueno H
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():137-41. PubMed ID: 16983765
    [No Abstract]   [Full Text] [Related]  

  • 3. Delaying the incubation phase from obesity to cardiovascular disease.
    Cardiovasc J S Afr; 2006; 17(5):272-3. PubMed ID: 17117238
    [No Abstract]   [Full Text] [Related]  

  • 4. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?
    Ridker PM; Wilson PW; Grundy SM
    Circulation; 2004 Jun; 109(23):2818-25. PubMed ID: 15197153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein, inflammation, and cardiovascular disease: clinical update.
    Ridker PM
    Tex Heart Inst J; 2005; 32(3):384-6. PubMed ID: 16392225
    [No Abstract]   [Full Text] [Related]  

  • 6. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease.
    Haffner SM
    Am J Cardiol; 2006 Jan; 97(2A):3A-11A. PubMed ID: 16442931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory markers and the metabolic syndrome.
    Athyros VG; Elisaf M; Mikhailidis DP
    Atherosclerosis; 2005 Nov; 183(1):187-8. PubMed ID: 16054632
    [No Abstract]   [Full Text] [Related]  

  • 8. High-sensitivity C-reactive protein in every chart? The use of biomarkers in individual patients.
    Ben-Yehuda O
    J Am Coll Cardiol; 2007 May; 49(21):2139-41. PubMed ID: 17531664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metabolic syndrome].
    Alizadeh Dehnavi R; Tamsma JT
    Ned Tijdschr Geneeskd; 2005 Oct; 149(42):2377; author reply 2377-8. PubMed ID: 16261723
    [No Abstract]   [Full Text] [Related]  

  • 10. The inflammatory hypothesis: any progress in risk stratification and therapeutic targets?
    Blankenberg S; Yusuf S
    Circulation; 2006 Oct; 114(15):1557-60. PubMed ID: 17030701
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cardiovascular risk prediction and its relationship with metabolic syndrome and emerging serum makers in occupational health surveillance].
    Reinoso-Barbero L; Capapé-Aguilar A; Díaz-Garrido R; Santiago Dorrego C; Gómez-Gallego F; Bandrés Moya F
    Arch Prev Riesgos Labor; 2014; 17(2):91-6. PubMed ID: 24718631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter by Ridker and Everett regarding article, "The inflammatory hypothesis: any progress in risk stratification and therapeutic targets?".
    Ridker PM; Everett BM
    Circulation; 2007 May; 115(20):e475; author reply e476. PubMed ID: 17515471
    [No Abstract]   [Full Text] [Related]  

  • 13. [Does JUPITER change the daily routine of our practice?].
    Schlossberg D
    Praxis (Bern 1994); 2009 Mar; 98(6):302. PubMed ID: 19291635
    [No Abstract]   [Full Text] [Related]  

  • 14. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
    Jialal I; Smith G
    Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574
    [No Abstract]   [Full Text] [Related]  

  • 15. High-Sensitivity C-Reactive Protein and Statin Initiation.
    Trpkovic A; Stanimirovic J; Rizzo M; Resanovic I; Soskic S; Jevremovic D; Isenovic ER
    Angiology; 2015 Jul; 66(6):503-7. PubMed ID: 25053677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-reactive protein and cardiovascular risk: more fuel to the fire.
    Boekholdt SM; Kastelein JJ
    Lancet; 2010 Jan; 375(9709):95-6. PubMed ID: 20031200
    [No Abstract]   [Full Text] [Related]  

  • 17. Metabolic syndrome and carotid intima-media thickness in young adults: roles of apolipoprotein B, apolipoprotein A-I, C-reactive protein, and secretory phospholipase A2: the cardiovascular risk in young Finns study.
    Mattsson N; Magnussen CG; Rönnemaa T; Mallat Z; Benessiano J; Jula A; Taittonen L; Kähönen M; Juonala M; Viikari JS; Raitakari OT
    Arterioscler Thromb Vasc Biol; 2010 Sep; 30(9):1861-6. PubMed ID: 20539018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin therapy for the metabolic syndrome: the evidence base.
    Jialal I; Devaraj S
    Metab Syndr Relat Disord; 2009 Oct; 7(5):393-6. PubMed ID: 19731996
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter by Timpson et al regarding article, "Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level".
    Timpson NJ; Smith GD; Ebrahim S
    Circulation; 2006 Aug; 114(7):e256. PubMed ID: 16908780
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiometabolic risk modification: current trends and emerging therapies.
    Lillo JL; Bray G; Woods SC; Henry RR; Hadley RD
    JAAPA; 2006 Dec; Suppl Cardiometabolic():3-14; quiz 15-6. PubMed ID: 17354517
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.